PHARMA MAR, S.A. from 31/01/2023 to 31/01/2023 31/01/2023 08:27 PHARMA MAR, S.A. On business and financial situation The Company announces the approval of Zepzelca® (lurbinectedin) for the treatment of metastatic Small Cell Lung Cancer in Israel Register number: 20212